Literature DB >> 29884668

Systolic heart failure in a patient with primary aldosteronism.

Chikezie Alvarez1, Vinuta Mohan2.   

Abstract

A 53-year-old African man with a 25-year history of uncontrolled hypertension and systolic heart failure presented with an acute congestive heart failure exacerbation. He was found to have severe hypokalaemia, so additional testing was performed, and primary aldosteronism was confirmed. CT scan showed a 1.2×2.4 cm well-defined, homogeneous adenoma of the left adrenal gland. Adrenal vein sampling confirmed unilateral primary aldosteronism with lateralisation to the left adrenal gland. The patient was started on spironolactone and was referred to surgery for laparoscopic left adrenalectomy. Primary aldosteronism is associated with high cardiovascular morbidity and mortality due to activation of cardiac mineralocorticoid receptors. Studies suggest these negative effects can be reduced with early intervention and treatment. This case highlights the importance of investigating secondary causes of hypertension in young patients and the potential adverse cardiac effects of primary aldosteronism when it goes undiagnosed and untreated for years. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  adrenal disorders; heart failure; hypertension

Mesh:

Substances:

Year:  2018        PMID: 29884668      PMCID: PMC6011484          DOI: 10.1136/bcr-2018-225145

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Aldosterone and mineralocorticoid receptors in the cardiovascular system.

Authors:  John W Funder
Journal:  Prog Cardiovasc Dis       Date:  2010 Mar-Apr       Impact factor: 8.194

Review 2.  Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.

Authors:  Johann Bauersachs; Frédéric Jaisser; Robert Toto
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

3.  Double hit! A unique case of resistant hypertension.

Authors:  Kristen Elizabeth DeCarlo; Nidhi Agrawal
Journal:  BMJ Case Rep       Date:  2017-12-22

4.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

5.  Observational study mortality in treated primary aldosteronism: the German Conn's registry.

Authors:  Martin Reincke; Evelyn Fischer; Sabine Gerum; Katrin Merkle; Sebastian Schulz; Anna Pallauf; Marcus Quinkler; Gregor Hanslik; Katharina Lang; Stefanie Hahner; Bruno Allolio; Christa Meisinger; Rolf Holle; Felix Beuschlein; Martin Bidlingmaier; Stephan Endres
Journal:  Hypertension       Date:  2012-07-23       Impact factor: 10.190

6.  Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.

Authors:  Yen-Hung Lin; Xue-Ming Wu; Hsiu-Hao Lee; Jen-Kuang Lee; Yu-Chun Liu; Hung-Wei Chang; Chien-Yu Lin; Vin-Cent Wu; Shih-Chieh Chueh; Lung-Chun Lin; Men-Tzung Lo; Yi-Lwun Ho; Kwan-Dun Wu
Journal:  J Hypertens       Date:  2012-08       Impact factor: 4.844

7.  Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function.

Authors:  Achim Lother; Stefan Berger; Ralf Gilsbach; Stephan Rösner; Andreas Ecke; Frederico Barreto; Johann Bauersachs; Günther Schütz; Lutz Hein
Journal:  Hypertension       Date:  2011-02-14       Impact factor: 10.190

8.  Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.

Authors:  Cristiana Catena; GianLuca Colussi; Roberta Lapenna; Elisa Nadalini; Alessandra Chiuch; Pasquale Gianfagna; Leonardo A Sechi
Journal:  Hypertension       Date:  2007-09-24       Impact factor: 10.190

9.  Cardiovascular outcomes in patients with primary aldosteronism after treatment.

Authors:  Cristiana Catena; GianLuca Colussi; Elisa Nadalini; Alessandra Chiuch; Sara Baroselli; Roberta Lapenna; Leonardo A Sechi
Journal:  Arch Intern Med       Date:  2008-01-14

10.  Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study.

Authors:  Sébastien Savard; Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

View more
  1 in total

1.  Spironolactone Inhibits Cardiomyocyte Hypertrophy by Regulating the Ca2+/Calcineurin/p-NFATc3 Pathway.

Authors:  Xin Wang; Wenting Zhang; Jingtao Na; Yanping Huo; Yacheng Wang; Ketong Liu
Journal:  J Healthc Eng       Date:  2021-12-16       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.